The potential efficacy of dasatinib combination therapy in children and adolescents and young adults with de novo ALL with ABL-class mutations and Ph-like ALL is being investigated in the phase 3 COG AALL1131 trial (NCT01406756) and the SJCRH Total XVII trial (NCT03117751). This evidence concerns the gene ABL1 and acute lymphoblastic leukemia.